Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years of age.
Metastatic disease.
One previous treatment including docetaxel (Taxotere).
At least 3 weeks since last surgery/radiation/chemotherapy
ECOG Performance Status of 0, 1 or 2
You may not be if
Active brain metastases
Clareo Health | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
